Table of Contents - WOC 2012

WOC2012 Abstract Book
Free Paper: Retina- Medical
Sun 19 Feb 10:30 - 12:00 Conference Room B4
FP-RET-SU 294 (1)
Role of Brimonidine in the Treatment of Clinically Significant Macular
Edema with Ischemic Changes in Diabetic Maculopathy
Sood Sunandan (1) , Chawla Parul, Narang Subina
1. Department of Ophthalmology, Government Medical College Hospital
Objective and Purpose: To evaluate the role of brimonidine (BMD) in the
management of clinically significant macular edema (CSME) with ischemic
changes.
Methods: The study included 30 CSME eyes with ischemic macula. Group I
eyes consisted of 17 eyes of 17 diabetic patients who were administered
topical BMD (0.2%). Group II included 13 control eyes. Outcome parameters
included the mean change in logMAR visual acuity and any change in the
grade of Foveal Avascular Zone (FAZ) size, outline, capillary non perfusion,
and capillary dilatation in the 2 groups as per EDTRS Report no. 11.
Results: In both the groups, there was significant improvement in visual acuity
in the sixth month (p=0.02) as compared from the first visit which was possibly
because of metabolically stable diabetic status in the two groups. Significant
decrease was found in FAZ area and radius in Group I (p=0.01) which was not
found within Group II (p=0.60) when first visit was compared to sixth month.
There was no significant difference in average grade of ischaemia in both
groups (p=0.39, 0.08).
Conclusion: It was concluded that BMD may have a role in the treatment of
clinically significant macular edema with ischemic changes in diabetic
maculopathy.
FP-RET-SU 294 (2)
Different Dosages of Intravitreal Bevacizumab for ROP Newborn
Spandau Ulrich (1) , Tomic Zoran (1) , Holmstrom Gerd (1)
1. Department of Ophthalmology, University of Uppsala
Purpose: A lower dosage of bevacizumab might decrease the risk of possible
ocular and systemic side-effects. The purpose was to discuss different dosages
of bevacizumab therapy in ROP newborn.
Methods: Seven infants with a mean weight of 586g and a mean GA of 24.0
weeks were treated with bevacizumab therapy (0.4 and 0.625 mg) or laser.
The dosage of 0.625 mg was chosen according to the recommendations of
the BEAT-ROP study. The dosage of 0.4 was calculated that the neonate eye
volume is 3-4 times smaller than the adults eye volume (axial length 34 week
GA neonate=16 mm).
Results: All infants (5 male and 2 female) had plus disease. The mean
treatment time was GA of 34.2 weeks. Three newborn were treated with
lasertherapy or cryopexy and after recurrence with 0.625mg bevacizumab.
Two newborn were treated with a single injection of 0.625mg bevacizumab and
required later lasertherapy. Two newborn were treated with a single injection of
0.4mg bevacizumab only. Major complications included a macular dragging in
one eye of a primary laser treated patient.
Conclusions: These and other results indicate that apparently half of the
dosage of which is recommended in the BEAT-ROP study could be sufficient
to treat ROP.
284
FP-RET-SU 294 (3)
A Novel Mutation of Unilateral Best Vitelliform Macular Dystrophy in
Chinese People
Ma Kai (1) , Gu Hong (1) , Yang Xiufen (1) , Xu Jun (1) , Liu Ningpu (1)
1. Beijing Tongren Hospital, Capital Medical University
Objective: To report a novel BEST1 gene mutation in two patients with unilateral
Best vitelliform macular dystrophy.
Methods: Best-corrected visual acuity, dilated fundus examination, and electrooculography,
fundus fluorescein angiography and autofluorescence
photography were performed in the two patients with Best macular dystrophy
and one of their relative. Both the patients and their relative also had blood
samples drawn, direct sequencing of PCR-amplified DNA fragments,
corresponding to the all 11 exons of the gene.
Results: A heterozygous BEST1 gene missense mutation in exon 4(Arg105Gly
[CGC_GGC]) was identified in both patients. This mutation was not present
in their relative and the other 50 normal peoples whose blood sample were
analysis as control in this study. Clinical examination confirmed that the lesions
affected the patients unilaterally.
Conclusions: A novel mutation in the BEST1gene (C313G) was found in two
Chinese patients whose phenotype and electrooculographic findings were
characteristic of unilateral Best macular dystrophy.
FP-RET-SU 294 (4)
Vitreomacular Traction Leading to Pseudo-active OCT Appearances
in cases of Ranibizumab Treated CNV
Zachariah Sonia (1) , Livingstone Iain (2) , Koshy Zachariah (3)
1. Southern General Hospital
2. Gartnavel General Hospital
3. Ayr Hospital
Aim: To highlight a pseudo-active OCT appearance secondary to vitreomacular
traction in quiescent post ranibizumab treated CNV.
Method: Case series with OCT and FFA images.
Results: 5 cases undergoing treatment with ranibizumab for AMD related CNV
continued to show intra and subretinal fluid on OCT despite visual stability and
absent leakage on FFA.
Conclusion: Vitreomacular traction can cause abnormal OCT appearance
despite evidence of an inactive CNV membrane following antiVEGF treatment
for AMD.
FP-RET-SU 294 (5)
Overview of Central Retinal Vein Occlusion in Retinal Unit of Eye
Foundation Hospital Group Lagos - Nigeria
Akinwale Akinfe
1. Eye Foundation Hospital Group
Objective: Determine the significance of fundus florescein angiography, optical
coherence tommography, and post panretinal photocoagulation/intravitreal
vascular endothelial growth factor visual outcome of cases (African descent)
attending eye foundation hospital group
Methods: Descriptive study.
Result: Better visual outcome with appropriate diagnostic facilities and
therapeutic interventions among African descent.
Conclusion: Better visual outcome in non-ischeamic central retina vein
occlusion cases than ischemic central retina vein occlusion cases among
African descent.